Nearly one-third (33%) of patients with relapsed/refractory multiple myeloma (RRMM) achieved ≥5 years of progression-free survival (PFS) after a single cilta-cel infusion.
Long-term survivors showed specific biomarker profiles, including lower tumor burden and higher effector-to-target (E:T) cell ratios.
Cilta-cel maintained a consistent safety profile, with no new long-term safety signals identified over five years of follow-up.
This result challenges historical expectations for RRMM, where median PFS is typically less than six months, and median overall survival (OS) is about a year.
